Extractables and Leachables in Pharmaceutical Products: Potential Adverse Effects and Toxicological Risk Assessment.

Area of Science:

• Pharmaceutical Science
• Toxicology
• Regulatory Science

Background:

• Drug products interact with various materials during manufacturing, storage, and administration, leading to potential leachable contaminants.
• Leachables can negatively impact drug product quality, including stability, efficacy, and physical attributes, and pose direct risks to patient safety due to inherent toxicity.

Purpose of the Study:

• To provide an overview of toxicological limits for extractables and leachables (E/L) analysis.
• To outline the workflow for toxicological risk assessment of E/L, including mutagenicity and other endpoints.
• To interpret the draft ICH Q3E guideline and its impact on global E/L safety assessments.

Main Methods:

• Review of toxicological limits and their translation into analytical limits for E/L.
• Description of a workflow for toxicological risk assessment of E/L.
• Analysis of the draft International Council for Harmonisation (ICH) Q3E guideline.

Main Results:

• The study details the process of establishing and applying toxicological limits for E/L.
• A comprehensive workflow for risk assessment, encompassing various toxicological endpoints, is presented.
• The draft ICH Q3E guideline is highlighted as a key development for harmonizing E/L safety evaluations.

Conclusions:

• Comprehensive toxicological evaluation of leachables is essential for ensuring drug product quality and patient safety.
• Understanding and applying the ICH Q3E guideline is crucial for pharmaceutical development and regulatory strategies.
• Emerging challenges necessitate continuous advancements in scientific methodologies and regulatory frameworks for E/L assessment.